The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity
Open accessAbstract
IgA nephropathy (IgAN) is characterized by circulating immune complexes composed of galactose-deficient IgA1 and a glycan-specific IgG antibody.These immune complexes deposit in the glomerular mesangium and induce the mesangioproliferative glomerulonephritis characteristic of IgAN.To define the precise specificities and molecular properties of the IgG antibodies, we generated EBV-immortalized IgG-secreting lymphocytes from patients with IgAN and found that the secreted IgG formed complexes with galactose-deficient IgA1 in a glycan-dependent manner.We cloned and sequenced the heavy-and light-chain antigen-binding domains of IgG specific for galactose-deficient IgA1 and identified an A to S substitution in the complementarity-determining region 3 of the variable region of the gene encoding the IgG heavy chain in IgAN patients.Furthermore, site-directed mutagenesis that reverted the residue to alanine reduced the binding of recombinant IgG to galactose-deficient IgA1.Finally, we developed a dot-blot assay for the glycan-specific IgG antibody that differentiated patients with IgAN from healthy and disease controls with 88% specificity and 95% sensitivity and found that elevated levels of this antibody in the sera of patients with IgAN correlated with proteinuria.Collectively, these findings indicate that glycan-specific antibodies are associated with the development of IgAN and may represent a disease-specific marker and potential therapeutic target.Conflict of interest: The authors have declared that no conflict of interest exists.Nonstandard abbreviations used: CDR3, complementarity-determining region 3; dd-IgA1, desialylated and degalactosylated IgA1; DH, diversity region of IGH gene; Fab-IgA1, Fab fragment of Gal-deficient IgA1 containing the N-terminal part of the hinge region with O-glycans; Gal, galactose; GalNAc, N-acetylgalactosamine; HAA, Helix aspersa agglutinin; HR-BSA, synthetic IgA1 hinge-region peptide linked to BSA; HR-GalNAc-BSA, synthetic IgA1 hinge-region glycopeptide linked to BSA with 3 Gal-NAc residues; IgAN, IgA nephropathy; JH, joint region of IGH gene; rIgG, recombinant human IgG; ROC, receiver operating characteristic curve; UP/Cr, urinary protein/urinary creatinine (ratio); VH, variable region of IGH gene.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Somatic generation of antibody diversity
Tonegawa, S. (1983) · Nature · doi:10.1038/302575a0 · Cited by 4,005
Somatic generation of antibody diversity.
Matthyssens, G., Hozumi, N., & Tonegawa, S. (1976) · PubMed · Cited by 3,244
Predominant Autoantibody Production by Early Human B Cell Precursors
Wardemann, H., Yurasov, S., Schaefer, A., Young, J. W., Meffre, E., & Nussenzweig, M. C. (2003) · Science · doi:10.1126/science.1086907 · Cited by 2,083
Clonal selection and learning in the antibody system
Rajewsky, K. (1996) · Nature · doi:10.1038/381751a0 · Cited by 1,709
Tiller, T., Meffre, E., Yurasov, S., Tsuiji, M., Nussenzweig, M. C., & Wardemann, H. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2007.09.017 · Cited by 1,107
The Mechanism and Regulation of Chromosomal V(D)J Recombination
Bassing, C. H., Swat, W., & Alt, F. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00675-x · Cited by 967
[Intercapillary deposits of IgA-IgG].
Berger, J., & Hinglais, N. (1968) · PubMed · Cited by 800
Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities
Xu, J. L., & Davis, M. M. (2000) · Immunity · doi:10.1016/s1074-7613(00)00006-6 · Cited by 779 · cited 1×
“Normally, the CDR-H3 is located in the center of the antigen-binding sites and is the main determinant of antibody specificity (48).”
BackgroundHeptinstall's Pathology of the Kidney
Jennette, J. C., Heptinstall, R. H., Olson, J. L., Schwartz, M. M., & Silva, F. G. (2014) · Cited by 599
McKean, D., Huppi, K., Bell, M., Staudt, L., Gerhard, W., & Weigert, M. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.10.3180 · Cited by 547
Cited by
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
Jennette, J. C., Falk, R. J., Bacon, P. A., Basu, N., Cid, M. C., Ferrario, F., Flores‐Suarez, L. F., Gross, W. L., Guillevin, L., Hagen, E. C., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.37715 · Cited by 6,631
The Pathophysiology of IgA Nephropathy
Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A. B., Renfrow, M. B., Wyatt, R. J., Scolari, F., Mestecky, J., Gharavi, A. G., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011050464 · Cited by 910
Self-citationThe immune system and kidney disease: basic concepts and clinical implications
Kurts, C., Panzer, U., Anders, H.-J., & Rees, A. J. (2013) · Nature Reviews Immunology · doi:10.1038/nri3523 · Cited by 696
Immune and Inflammatory Role in Renal Disease
Imig, J. D., & Ryan, M. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120028 · Cited by 356
Current Understanding of the Role of Complement in IgA Nephropathy
Maillard, N., Wyatt, R. J., Julian, B. A., Kiryluk, K., Gharavi, A., Fremeaux-Bacchi, V., & Novak, J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014101000 · Cited by 338
Self-citationFloege, J., & Amann, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00272-5 · Cited by 306
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy
Magistroni, R., D’Agati, V. D., Appel, G. B., & Kiryluk, K. (2015) · Kidney International · doi:10.1038/ki.2015.252 · Cited by 302
Lafayette, R. A., Canetta, P. A., Rovin, B. H., Appel, G. B., Novak, J., Nath, K. A., Sethi, S., Tumlin, J. A., Mehta, K., Hogan, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060640 · Cited by 300
Self-citationMice overexpressing BAFF develop a commensal flora–dependent, IgA-associated nephropathy
McCarthy, D. D., Kujawa, J., Wilson, C., Papandile, A., Poreci, U., Porfilio, E. A., Ward, L., Lawson, M. A. E., Macpherson, A. J., McCoy, K. D., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45563 · Cited by 286
Self-citationAutoantibodies Targeting Galactose-Deficient IgA1 Associate with Progression of IgA Nephropathy
Berthoux, F., Suzuki, H., Thibaudin, L., Yanagawa, H., Maillard, N., Mariat, C., Tomino, Y., Julian, B. A., & Novak, J. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012010053 · Cited by 272
Self-citationKiryluk, K., Moldoveanu, Z., Sanders, J. T., Eison, T. M., Suzuki, H., Julian, B. A., Novak, J., Gharavi, A. G., & Wyatt, R. J. (2011) · Kidney International · doi:10.1038/ki.2011.16 · Cited by 266
Self-citationRoberts, I. S. D. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.92 · Cited by 263
Henoch–Schönlein purpura nephritis in children
Davin, J.-C., & Coppo, R. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.126 · Cited by 257
The pathogenesis of IgA nephropathy and implications for treatment
Cheung, C. K., Alexander, S., Reich, H. N., Selvaskandan, H., Zhang, H., & Barratt, J. (2025) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00885-3 · Cited by 222
Corticosteroid therapy in IgA nephropathy
Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111112 · Cited by 190
Metadata
- Authors
- Suzuki, H., Fan, R., Zhang, Z., Brown, R., Hall, S., Julian, B. A., Chatham, W. W., Suzuki, Y., Wyatt, R. J., Moldoveanu, Z., Lee, J. Y., Robinson, J., Tomana, M., Tomino, Y., Mestecky, J., & Novak, J.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-05-26
- Volume
- 119
- Issue
- 6
- Pages
- 1668-77
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2137421192
- Cited by
- 450
- References
- 34
- FWCI
- 18.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.